May 18, 2016 / 6:35 AM / 4 years ago

AstraZeneca's Lynparza fails in gastric cancer combination test

The logo of AstraZeneca is seen on a medication package in a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth

LONDON (Reuters) - AstraZeneca’s recently approved ovarian cancer drug Lynparza failed to increase overall survival significantly when given with chemotherapy to patients with gastric cancer in a late-stage trial, the drugmaker said on Wednesday.

The news is a setback for the British drugmaker, which reported positive results with an experimental acute asthma drug on Tuesday, although the result may have limited read-across for Lynparza in other cancer settings.

AstraZeneca said it was disappointed, but noted this particular trial was unusual in using a low dose and combining Lynparza with a standard chemotherapy.

The company has high hopes for Lynparza, which is central to its goal of building a portfolio of compounds targeting DNA damage response (DDR) mechanisms in cancer cells.

Reporting by Ben Hirschler; Editing by Mark Potter

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below